Navigation Links
Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
Date:6/12/2008

- Phase 2 data demonstrate sustained improvement in disease activity

through three years of LymphoStat-B (belimumab) therapy - - No increase in adverse events, malignancies, infections or laboratory

abnormalities over time -

ROCKVILLE, Md., June 12 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of results from a long- term Phase 2 continuation trial showing that LymphoStat-B(R) (belimumab) was associated with sustained improvement in disease activity across multiple clinical measures, decreased frequency of disease flares, potential steroid- sparing activity, and was generally well tolerated through three years on treatment in combination with standard of care in patients with serologically active systemic lupus erythematosus (SLE). The results are the subject of a number of oral and poster presentations today in Paris at the 2008 Congress of the European League Against Rheumatism (EULAR).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )

"Based on the results presented at EULAR 2008, the clinical benefit observed for belimumab at Week 52 of this Phase 2 study appears to be durable through three years," said Richard Furie, M.D., Chief, Division of Rheumatology and Allergy-Clinical Immunology, North Shore Long Island Jewish Health System, Lake Success, NY, and Associate Professor of Medicine, New York University School of Medicine. "We observe that patients who crossed over from placebo to belimumab after Week 52 have also shown improvement across multiple clinical measures. The durability of clinical effect and the favorable safety p
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
3. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
4. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
5. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
6. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
7. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. First Human Implant of New Archus Orthopedics Facet Replacement System
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
(Date:5/17/2013)... May 17, 2013  Boston Scientific Corporation (NYSE: ... annual EuroPCR Scientific Program May 21-24 in ... present a particularly rich and diversified set of data ... , M.D., global chief medical officer, Boston Scientific.  ... presented, including the NG PROMUS trial, which evaluated our ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... TRIANGLE PARK, N.C. , May 6 Chimerix, Inc., ... Thomas A. Pitler , Ph.D., has joined the company as Vice ... , , ... of experience, combining skills in business development and strategic planning with ...
... Intercell AG (VSE: ICLL) today announced that it has signed an agreement ... discovery. The technology is based on expression cloning of monoclonal antibodies from ... treat infectious diseases. , , ... the agreed terms Intercell will pay EUR 15 million to ...
Cached Medicine Technology:Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development 2Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development 3Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases 2
(Date:5/19/2013)... Chicago, IL (PRWEB) May 19, 2013 In ... Surge, LLC, E-dentist.com has announced the launch of an SEO ... help dentists get high rankings in Google. , http://www.e-dentists.com/ ... do not pay for the service until they see results. ... sites. The lead generation websites run by JD Media Surge, ...
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... The Pradaxa lawyers at Bernstein Liebhard ... convened for hundreds of Pradaxa bleeding lawsuits ... U.S. District Court, Southern District of Illinois. According ... 14th, the Conference addressed the status of depositions and ... Conference that Defendants submitted a list of early trial ...
(Date:5/19/2013)... 2013 Vegas Hotel Escapes, the premier ... announce the launch it's all new vacation packages for ... on 5/19/2013. Consumers traveling to Las Vegas will be ... on VegasHotelEscapes.com's website. Travelers will be pleased to know ... price. , Vegas Hotel Escapes specializes in helping consumers ...
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
Breaking Medicine News(10 mins):Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2
... ... Two books provide a new way ... Literacy" is designed for teachers, and "HandMade Marks" is designed ... evaluation tools, hands-on exercises, and research questions, while also addressing ...
... ... UC-II®, is included in a new product from Nordic Naturals, the industry leader in ... 2010 Natural Products Expo West with great feedback from attendees looking for the latest, ... ...
... Those with abnormalities at initial screening often didn,t have ... News) -- Black Americans are less likely than whites ... on a flexible sigmoidoscopy screening test, says a new ... be at greater risk for colorectal cancer and more ...
... frequent returns to hospital for treatment, at higher rates than ... sickle cell disease often visit hospitals repeatedly in search of ... researchers found that one-third of sickle cell patients who visited ... relief. Young people, between the ages of 18 and 30, ...
... Mich.---The proportion of older middle-aged Americans who report disabilities ... in contrast to the disability decline that has been ... a new study by the RAND Corporation and the ... the proportion of Americans aged 50 to 64 who ...
... LOUIS -- In a broad-based review of studies focused on ... no evidence supporting the use of so-called "natural" treatments in ... wort, kava extract and valerian, herbal remedies touted on the ... anxiety wrote Kimberly Zoberi, M.D., associate professor of family and ...
Cached Medicine News:Health News:The Child's Way into Literacy: A New Look at Scribbling and Drawing 2Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 2Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 3Health News:InterHealth's UC-II in New Joint-Health Product from Nordic Naturals 4Health News:Blacks Less Likely to Get Follow-Up Colon Screening 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 2Health News:Sickle Cell Disease Patients Seek Acute Pain Care Repeatedly 3Health News:Middle-aged Americans report more mobility-related disabilities 2Health News:Middle-aged Americans report more mobility-related disabilities 3
... Respiratory Products, ,Westmed designs, manufacturers and ... and Respiratory professionals. Our mission is to ... clinician's ability to deliver quality medical care ... line. , ,Our web site is ...
... achieves optimum lung penetration for maximum therapeutic ... 1.04-1.10 µ at 6-8 LPM. Latex-free components. ... ,As the world leader in airway management ... of proven technology by offering top brands ...
... need for makeshift, modified nebulizer setups to ... gathering parts when your patient is critical? ... the utmost in Heliox rescue therapy. In ... becoming the standard of care in hospitals ...
... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
Medicine Products: